![Andreas Busch](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 5 M $ in data 30/06/2026
Andreas Eugen Busch is an Independent Outside Director at Astellas Pharma, Inc. since 2025 and an Independent Director at Sun Pharmaceutical Industries Ltd. since 2026.
Former roles include Vice Chairman-Supervisory Board at Centogene NV from 2022 to 2023, Chief Scientific Officer & Executive VP at Shire Plc from 2018 to 2019, Chief Scientific Officer at Cyclerion Therapeutics, Inc. from 2021 to 2022, Chief Innovation Officer at Absci Corp.
from 2022 to 2026, Head-Global Drug Discovery at Bayer Pharma AG from 2016 to 2017, Executive Vice President & Head-Drug Discovery at Bayer Animal Health from 2016 to 2017, Executive VP & Head-Global Drug Discovery at Bayer HealthCare AG from 2006 to 2015, Head-Cardiovascular Research at Aventis Pharma AG in 2005, Head-Cardiovascular Research at Hoechst Marion Roussel, Inc. from 1997 to 1999, and Global Head-Cardiovascular Research at Sanofi-Aventis Groupe SA from 1997 to 2005.
Also served as Professor at Johann Wolfgang Goethe-Universität Frankfurt am Main and Member-Supervisory Board at Max-Delbrück-Centrum für Molekulare Medizin (MDC).
Education includes a doctorate from Johann Wolfgang Goethe-Universität Frankfurt am Main conferred in 1989.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
ABSCI CORPORATION 0,25% | 31/03/2026 | 421.446 ( 0,25% ) | 5 M $ | 30/06/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| SUN PHARMACEUTICAL INDUSTRIES LTD. | Direttore/Membro del Consiglio | 12/05/2026 |
| Società | Posizione | Fine |
|---|---|---|
| ABSCI CORPORATION | Direttore/Membro del Consiglio | 04/10/2022 |
| CENTOGENE N.V. | Direttore/Membro del Consiglio | 12/12/2023 |
| CYCLERION THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | 30/09/2022 |
| SHIRE | Direttore Tecnico/Scientifico/R&S | 01/03/2019 |
Bayer Pharma AG
 Bayer Pharma AG Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Corporate Officer/Principal | 01/12/2017 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 14 |
|---|---|
Shire Plc
 Shire Plc Pharmaceuticals: MajorHealth Technology Develops and markets medicines for patients with rare diseases | Health Technology |
Sun Pharmaceutical Industries Ltd.
 Sun Pharmaceutical Industries Ltd. Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical ingredients | Health Technology |
Bayer HealthCare AG
 Bayer HealthCare AG Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals, healthcare supplements and crop herbicides | Health Technology |
Astellas Pharma, Inc.
 Astellas Pharma, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceuticals and related medical products | Health Technology |
Johann Wolfgang Goethe-Universität Frankfurt am Main
 Johann Wolfgang Goethe-Universität Frankfurt am Main Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bayer Pharma AG
Bayer Pharma AG Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Aventis Pharma AG | |
Hoechst Marion Roussel, Inc.
 Hoechst Marion Roussel, Inc. Pharmaceuticals: GenericHealth Technology Develops, manufactures and sells generic pharmaceutical products | Health Technology |
Max-Delbrück-Centrum für Molekulare Medizin (MDC)
 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Miscellaneous Commercial ServicesCommercial Services Operates as a biomedical research institute | Commercial Services |
Bayer Animal Health
 Bayer Animal Health Pharmaceuticals: MajorHealth Technology Provides healthcare and pharmaceutical medicines | Health Technology |
Sanofi-Aventis Groupe SA
 Sanofi-Aventis Groupe SA Financial ConglomeratesFinance Functions as an investment holding company | Finance |
Absci Corp.
 Absci Corp. BiotechnologyHealth Technology Engages in development of cutting-edge protein production technologies committed to reducing costs in the biopharmaceutical industry | Health Technology |
Cyclerion Therapeutics, Inc.
 Cyclerion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and distributes pharmaceutical products for serious and orphan diseases | Health Technology |
Centogene NV
 Centogene NV Medical SpecialtiesHealth Technology Provides genetic diagnostic analyses of rare inherited diseases | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
